Trial Profile
A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI≥3) Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Avadomide (Primary) ; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisone; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 28 Apr 2021 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results analysing the safety and efficacy of avadomide plus R-CHOP in previously untreated patients with high-risk DLBCL presented at the 25th Congress of the European Haematology Association
- 31 May 2020 Results (n=35; as 30 July 2019) of phase 1 part of the study evaluating efficacy and safety presented at the 56th Annual Meeting of the American Society of Clinical Oncology